CENTRE ANTOINE LACASSAGNE

C A L MEDICYC, Nice, Provence Alpes Cote D Azur, Francewww.centreantoinelacassagne.org/frEstablished: 1961-01-01

Also known as:

laboratoire du cal

Clinical Trials

21 active

Approvals

Total approvals

Agencies

Regulatory bodies

Founded

1961

Overview

Trial Phase Distribution

Phase

Trials

Not Applicable

44.6%

Phase 1

20.5%

Phase 2

14.5%

Phase 3

2.4%

Phase 4

1.2%

Trial Status Distribution

Active, not recruiting

24.1%

Completed

44.6%

Not yet recruiting

1.2%

Recruiting

20.5%

Suspended

1.2%

Terminated

3.6%

Unknown

1.2%

Withdrawn

3.6%

Clinical Trials

Trials sponsored by this organization (83)

Pharmacokinetic Study of Pembrolizumab and Its Impact on Immunity and the Tumor Microenvironment, Which May Explain the Efficacy of Post-immunotherapy Chemotherapy.

Phase 4

Not yet recruiting

interventional

Oct 2026110 participants

Assessment of Adherence to Remotely Monitored Physical Activity Tracked on a Smartwatch, and Its Impact on Reducing Fatigue 3 Months After Adjuvant Chemotherapy for Cancer

Not Applicable

Recruiting

interventional

Sep 202698 participants

Locally Advanced NSCLC Treated With Radiochemotherapy: Phase 2 Study on the Value of a Stereotactic Boost

Phase 2

Recruiting

interventional

Jun 202542 participants

Development of Preclinical Models Derived From Tumors With a Molecular Abnormality of Interest to Test Their Sensitivity to New Anti-tumor Therapies.

Not Applicable

Recruiting

interventional

May 202550 participants

Study on the Contribution of the Genetic Tumor Profile Obtained by Circulating Tumor DNA Analysis in the Multidisciplinary Molecular Biology Meeting of Eastern PACA

Not Applicable

Recruiting

interventional

Mar 2025238 participants

Study of Cerebral Vascular Reserve Using Pharmacological Testing With Acetazolamide: A Non-Inferiority Study of PET Method Compared to Conventional Reference Scintigraphy

Not Applicable

Active, not recruiting

interventional

Jan 202519 participants

STUDY AGORA-1 / ALFA 2100:Phase 2 on the combinaison of Gemtuzumab Ozogamicin witk gilteritinib in adult patients with acute myeloid leukemia (AML) with a relapsed or refractory FLT3 mutation.

Phase 1

Active, not recruiting

interventional

Jul 202430 participants

Comparison of the Efficacy of Cryotherapy Combined With Compression in Preventing Neuropathy

Not Applicable

Recruiting

interventional

Apr 202460 participants

Page 1 of 11

Approvals

No approval data available

News

No news articles found

Back to Organizations